Io Therapeutics
Private Company
Funding information not available
Overview
Io Therapeutics is a preclinical-stage biotech company pioneering nuclear receptor-targeted therapies, specifically retinoids and rexinoids, for oncology, neurodegeneration, and autoimmunity. Founded in 2008, the company leverages deep expertise in retinoic acid receptor (RAR) and retinoid X receptor (RXR) biology to develop novel compounds that could address significant unmet medical needs. As a private entity, it operates with a focused research and development model, aiming to advance its pipeline into clinical testing. Its approach targets fundamental disease mechanisms across multiple therapeutic areas, offering potential for first-in-class or best-in-class treatments.
Technology Platform
Discovery and development of synthetic retinoid and rexinoid small molecules that selectively target and modulate Retinoic Acid Receptors (RARs) and Retinoid X Receptors (RXRs) to regulate gene expression for therapeutic effect.
Opportunities
Risk Factors
Competitive Landscape
The field of nuclear receptor drug discovery is active, with competitors ranging from large pharmaceutical companies to biotechnology firms focused on specific receptors (e.g., PPARs, FXR) or disease areas. Io's specific focus on RAR/RXR for immuno-oncology, neurodegeneration, and autoimmunity is a niche but competitive space, requiring demonstration of superior selectivity and efficacy.